Download PDF
Pharmacopsychiatry 2019; 52(01): 38-43
DOI: 10.1055/s-0044-102009
Original Paper
© Georg Thieme Verlag KG Stuttgart · New York

QTc Time Correlates with Amitriptyline and Venlafaxine Serum Levels in Elderly Psychiatric Inpatients

Gudrun Hefner
1   Psychiatric Hospital, Vitos Klinik Hochtaunus, Friedrichsdorf, Germany
,
Martina Hahn
2   Psychiatric Hospital, Vitos Klinik Eichberg, Eltville, Germany
,
Matthias Hohner
3   Department of Psychiatry and Psychotherapy, University of Würzburg, Würzburg, Germany
,
Sybille C. Roll
2   Psychiatric Hospital, Vitos Klinik Eichberg, Eltville, Germany
,
Ansgar Klimke
1   Psychiatric Hospital, Vitos Klinik Hochtaunus, Friedrichsdorf, Germany
,
Christoph Hiemke
4   Department of Psychiatry and Psychotherapy, University Medical Center of Mainz, Germany
› Author Affiliations
Further Information

Publication History

received 19 October 2017
revised 12 December 2017

accepted 29 January 2018

Publication Date:
21 February 2018 (online)

Also available at
    Permissions and Reprints

Abstract

Introduction Many antidepressants cause QT prolongation but the classification of cardiac risk of these drugs varies markedly in different published lists. This retrospective study analyzed the correlation of QTc time with amitriptyline and venlafaxine serum level in elderly psychiatric inpatients.

Methods Elderly inpatients aged≥65 years for whom venlafaxine or amitriptyline serum level had been measured were selected retrospectively from a therapeutic drug monitoring database and screened for an electrocardiogram measurement at the time of blood withdrawal. The correlation of amitriptyline or venlafaxine serum levels with QTc time was examined by using Pearson’s correlation analysis.

Results Amitriptyline serum levels (n=11) correlated significantly with QTc time (r=0.918, p<0.001, CI 95%). Venlafaxine serum levels (n=27) also correlated significantly with QTc time (r=0.382, p<0.05, CI 95%).

Discussion Amitriptyline and venlafaxine induce QT prolongation depending on drug concentrations in blood. Its extent, however, is very low when drug serum levels are within the therapeutic range. Future pharmacokinetic studies that correlate drug serum level and QT time should classify the cardiac risk of drugs based on the grade of the regression line in relation to the therapeutic range.

Key words

amitriptyline - venlafaxine - serum level - QT prolongation - therapeutic drug monitoring
 

  • References

  • 1 Fulton MM, Allen ER. Polypharmacy in the elderly: A literature review. J Am Acad Nurse Pract. 2005; 17: 123-132
    CrossrefPubMedGoogle Scholar
  • 2 Wenzel-Seifert K, Wittmann M, Haen E. QTc prolongation by psychotropic drugs and the risk of Torsade de Pointes. Dtsch Arztebl Int 2011; 108: 687-693
    PubMedGoogle Scholar
  • 3 Tisdale JE, Drug-induced QT. interval prolongation and torsades de pointes: Role of the pharmacist in risk assessment, prevention and management. Can Pharm J. 2016; 149: 139-152
    CrossrefPubMedGoogle Scholar
  • 4 Turnheim K. When drug therapy gets old: Pharmacokinetics and pharmacodynamics in the elderly. Exp Gerontol. 2003; 38: 843-853
    CrossrefPubMedGoogle Scholar
  • 5 Jeste DV, Alexopoulos GS, Bartels SJ. et al. Consensus statement on the upcoming crisis in geriatric mental health: Research agenda for the next 2 decades. Arch Gen Psychiatry. 1999; 56: 848-853
    CrossrefPubMedGoogle Scholar
  • 6 Lapid MI, Rummans TA. Evaluation and management of geriatric depression in primary care. Mayo Clin Proc. 2003; 78: 1423-1429
    CrossrefPubMedGoogle Scholar
  • 7 Holt S, Schmiedl S, Thurmann PA. Potentially inappropriate medications in the elderly: The PRISCUS list. Dtsch Arztebl Int 2010; 107: 543-551
    PubMedGoogle Scholar
  • 8 American Geriatrics Society 2015 Beers Criteria Update Expert Panel . American Geriatrics Society 2015 Updated Beers Criteria For Potentially Inappropriate Medication Use In Older Adults. J Am Geriatr Soc 2015; 63: 2227-2246
    CrossrefPubMedGoogle Scholar
  • 9 Hiemke C, Eckermann G. Kombinationstherapie/Polypharmazie. Arzneimitteltherapie 2014; 32 Jahrgang, Heft 12
    PubMedGoogle Scholar
  • 10 Benkert O, Hippius H. eds. Kompendium der Psychiatrischen Pharmakotherapie. 11th ed. Heidelberg: Springer; 2017
    Google Scholar
  • 11 Woosley RL, Heise CW, Romero KA.QTDrugs List. Accessed at: www.Crediblemeds.org Accession on October 10, 2017
    PubMed
  • 12 Mallet L, Spinewine A, Huang A. The challenge of managing drug interactions in elderly people. Lancet 2007; 370: 185-191
    CrossrefPubMedGoogle Scholar
  • 13 Nagler EV, Webster AC, Vanholder R. et al. Antidepressants for depression in stage 3-5 chronic kidney disease: A systematic review of pharmacokinetics, efficacy and safety with recommendations by European Renal Best Practice (ERBP). Nephrol Dial Transplant. 2012; 27: 3736-3745
    CrossrefPubMedGoogle Scholar
  • 14 McLean AJ, Le Couteur DG. Aging biology and geriatric clinical pharmacology. Pharmacol Rev. 2004; 56: 163-184
    CrossrefPubMedGoogle Scholar
  • 15 Hiemke C, Bergemann N, Clement HW et al. Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: Update. 2017 Pharmacopsychiatry 2017 Sep 14 [Epub ahead of print]
    PubMed
  • 16 Hefner G, Laib AK, Sigurdsson H. et al. The value of drug and metabolite concentration in blood as a biomarker of psychopharmacological therapy. Int Rev Psychiatry 2013; 25: 494-508
    CrossrefPubMedGoogle Scholar
  • 17 Chang KT, Shu HS, Chu CY. et al. Association between C-reactive protein, corrected QT interval and presence of QT prolongation in hypertensive patients. Kaohsiung J Med Sci. 2014; 30: 310-315
    CrossrefPubMedGoogle Scholar
  • 18 Kim E, Joo S, Kim J. et al. Association between C-reactive protein and QTc interval in middle-aged men and women. Eur J Epidemiol. 2006; 21: 653-659
    CrossrefPubMedGoogle Scholar
  • 19 Schmitt G, Herbold M, Peters F. Methodenvalidierung im Forensisch-Toxikologischen Labor. Walldorf, Germany: Arvecon; 2003
    Google Scholar
  • 20 Pedersen OL, Gram LF, Kristensen CB. et al. Overdosage of antidepressants: Clinical and pharmacokinetic aspects. Eur J Clin Pharmacol. 1982; 23: 513-521
    CrossrefPubMedGoogle Scholar
  • 21 Unterecker S, Pfuhlmann B, Kopf J. et al. Increase of heart rate and QTc by amitriptyline, but not by venlafaxine, is correlated to serum concentration. J Clin Psychopharmacol. 2015; 35: 460-463
    CrossrefPubMedGoogle Scholar
  • 22 Unterecker S, Warrings B, Deckert J. et al. Correlation of QTc interval prolongation and serum level of citalopram after intoxication - a case report. Pharmacopsychiatry 2012; 45: 30-34
    Article in Thieme ConnectPubMedGoogle Scholar
  • 23 Preskorn SH, Burke MJ, Fast GA. Therapeutic drug monitoring. Principles and practice. Psychiatr Clin North Am. 1993; 16: 611-645
    CrossrefPubMedGoogle Scholar
  • 24 Jaquenoud Sirot E, van der Velden JW, Rentsch K. et al. Therapeutic drug monitoring and pharmacogenetic tests as tools in pharmacovigilance. Drug Saf. 2006; 29: 735-768
    CrossrefPubMedGoogle Scholar
  • 25 Bengtsson F. Therapeutic drug monitoring of psychotropic drugs. TDM “nouveau”. Ther Drug Monit. 2004; 26: 145-151
    CrossrefPubMedGoogle Scholar
  • 26 Sigurdsson HP, Hefner G, Ben-Omar N. et al. Steady-state serum concentrations of venlafaxine in patients with late-life depression. Impact of age, sex and BMI. J Neural Transm (Vienna) 2015; 122: 721-729
    CrossrefPubMedGoogle Scholar
  • 27 Kokras N, Dalla C, Papadopoulou-Daifoti Z. Sex differences in pharmacokinetics of antidepressants. Expert Opin Drug Metab Toxicol 2011; 7: 213-226
    CrossrefPubMedGoogle Scholar
  • 28 Coupland C, Dhiman P, Morriss R. et al. Antidepressant use and risk of adverse outcomes in older people: Population based cohort study. BMJ 2011; 343: d4551
    CrossrefPubMedGoogle Scholar
  • 29 Waring WS. Clinical use of antidepressant therapy and associated cardiovascular risk. Drug Healthc Patient Saf 2012; 4: 93-101
    PubMedGoogle Scholar
  • 30 Hutton LMJ, Cave AJ, St-Jean R. et al. Should we be worried about QTc prolongation using citalopram? A review. J Pharm Pract 2017; 30: 353-358
    CrossrefPubMedGoogle Scholar
  • 31 Gerlach LB, Kales HC, Maust DT. et al. Unintended consequences of adjusting citalopram prescriptions following the 2011 FDA warning. Am J Geriatr Psychiatry 2017; 25: 407-414
    CrossrefPubMedGoogle Scholar